Tags

Type your tag names separated by a space and hit enter

Antarth, a polyherbal preparation protects against the doxorubicin-induced toxicity without compromising its Antineoplastic activity.
Phytother Res. 2005 Sep; 19(9):772-8.PR

Abstract

Doxorubicin (DOX), an anthracycline drug widely used for the treatment of various cancers, causes a cumulative dose-dependent cardiotoxicity that is characterized by an irreversible dilated cardiomyopathy and congestive heart failure. Antarth (ANT) a polyherbal preparation was evaluated for its cardioprotective properties against doxorubicin-induced cardiotoxicity in mice. Mice were treated with 25 mg/kg ANT orally once daily for 5 consecutive days before a single intraperitoneal injection of 15 mg/kg doxorubicin. The animals were killed 30 h after DOX treatment. DOX induced a significant elevation in the serum levels of glutamic pyruvic transaminase (GPT), glutamic oxaloacetic transaminase (GOT), creatine kinase (CK-MB) and lactate dehydrogenase (LDH), indicating its acute cardiotoxicity. The treatment of mice with ANT before DOX administration significantly reduced the serum levels of GPT, GOT, CK-MB and LDH indicating that ANT protected against the DOX-induced cardiotoxicity. Pretreatment of mice with 25 mg/kg ANT inhibited the DOX-induced decline in the antioxidant status. Intraperitoneal injection of 1.25 mg/kg DOX once daily for 9 consecutive days significantly improved the survival of mice bearing Ehrlich ascites carcinoma (EAC). Treatment of EAC with 25 mg/kg ANT alone did not affect the anticancer activity of DOX since ANT did not alter the tumor cell growth, the median survival time and average survival time of tumor bearing mice. The present study demonstrates that ANT protects mice against DOX-induced cardiotoxicity, without compromising the antineoplastic activity of DOX.

Authors+Show Affiliations

Department of Radiobiology, Kasturba Medical College, Manipal, India. gc.jagetia@rediffmail.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16220569

Citation

Jagetia, Ganesh Chandra, et al. "Antarth, a Polyherbal Preparation Protects Against the Doxorubicin-induced Toxicity Without Compromising Its Antineoplastic Activity." Phytotherapy Research : PTR, vol. 19, no. 9, 2005, pp. 772-8.
Jagetia GC, Reddy TK, Malagi KJ, et al. Antarth, a polyherbal preparation protects against the doxorubicin-induced toxicity without compromising its Antineoplastic activity. Phytother Res. 2005;19(9):772-8.
Jagetia, G. C., Reddy, T. K., Malagi, K. J., Nayak, B. S., Naidu, M. B., Ravikiran, P. B., Kamath, S. U., Shetty, P. C., & Reddy, D. S. (2005). Antarth, a polyherbal preparation protects against the doxorubicin-induced toxicity without compromising its Antineoplastic activity. Phytotherapy Research : PTR, 19(9), 772-8.
Jagetia GC, et al. Antarth, a Polyherbal Preparation Protects Against the Doxorubicin-induced Toxicity Without Compromising Its Antineoplastic Activity. Phytother Res. 2005;19(9):772-8. PubMed PMID: 16220569.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Antarth, a polyherbal preparation protects against the doxorubicin-induced toxicity without compromising its Antineoplastic activity. AU - Jagetia,Ganesh Chandra, AU - Reddy,Tiyyagura Koti, AU - Malagi,Krishna Jayacharya, AU - Nayak,Bijoor Shivananda, AU - Naidu,Menda Balachandra Rao, AU - Ravikiran,Penumurthy Balaji, AU - Kamath,Shobha Ullas, AU - Shetty,Prukash Chandra, AU - Reddy,Dondapati Subba, PY - 2005/10/13/pubmed PY - 2006/1/25/medline PY - 2005/10/13/entrez SP - 772 EP - 8 JF - Phytotherapy research : PTR JO - Phytother Res VL - 19 IS - 9 N2 - Doxorubicin (DOX), an anthracycline drug widely used for the treatment of various cancers, causes a cumulative dose-dependent cardiotoxicity that is characterized by an irreversible dilated cardiomyopathy and congestive heart failure. Antarth (ANT) a polyherbal preparation was evaluated for its cardioprotective properties against doxorubicin-induced cardiotoxicity in mice. Mice were treated with 25 mg/kg ANT orally once daily for 5 consecutive days before a single intraperitoneal injection of 15 mg/kg doxorubicin. The animals were killed 30 h after DOX treatment. DOX induced a significant elevation in the serum levels of glutamic pyruvic transaminase (GPT), glutamic oxaloacetic transaminase (GOT), creatine kinase (CK-MB) and lactate dehydrogenase (LDH), indicating its acute cardiotoxicity. The treatment of mice with ANT before DOX administration significantly reduced the serum levels of GPT, GOT, CK-MB and LDH indicating that ANT protected against the DOX-induced cardiotoxicity. Pretreatment of mice with 25 mg/kg ANT inhibited the DOX-induced decline in the antioxidant status. Intraperitoneal injection of 1.25 mg/kg DOX once daily for 9 consecutive days significantly improved the survival of mice bearing Ehrlich ascites carcinoma (EAC). Treatment of EAC with 25 mg/kg ANT alone did not affect the anticancer activity of DOX since ANT did not alter the tumor cell growth, the median survival time and average survival time of tumor bearing mice. The present study demonstrates that ANT protects mice against DOX-induced cardiotoxicity, without compromising the antineoplastic activity of DOX. SN - 0951-418X UR - https://www.unboundmedicine.com/medline/citation/16220569/Antarth_a_polyherbal_preparation_protects_against_the_doxorubicin_induced_toxicity_without_compromising_its_Antineoplastic_activity_ L2 - https://doi.org/10.1002/ptr.1713 DB - PRIME DP - Unbound Medicine ER -